Corporate Information And Statement Of Ifrs Compliance [Abstract]
| Concept |
As at 2024-12-31 |
2024-01-01 to 2024-12-31 |
As at 2023-12-31 |
|---|---|---|---|
| Corporate information and statement of IFRS compliance [abstract] | |||
| Domicile of entity | — |
England
|
— |
| Legal form of entity | — |
public company limited by shares
|
— |
| Address of entity's registered office | — |
|
— |
| Principal place of business | — |
OXB, a FTSE4Good constituent, is
|
— |
| Description of nature of entity's operations and principal activities | — |
The Group is a cell and gene therapy contract development and manufacturing organisation providing services to third parties as
|
— |
| Name of parent entity | — |
|
— |
| Disclosure of reclassifications or changes in presentation [text block] | — |
|
— |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [text block] | — | — | — |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [abstract] | |||
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items] | |||
| Current inventories |
13 ,57 3
GBP
|
— |
12 ,87 2
GBP
|
| Disclosure of material accounting policy information [text block] | — |
|
— |
| Disclosure of objectives, policies and processes for managing capital [text block] | — |
|
— |